ES8604308A1 - Un vector para producir un producto genetico por celulas de insectos - Google Patents

Un vector para producir un producto genetico por celulas de insectos

Info

Publication number
ES8604308A1
ES8604308A1 ES537766A ES537766A ES8604308A1 ES 8604308 A1 ES8604308 A1 ES 8604308A1 ES 537766 A ES537766 A ES 537766A ES 537766 A ES537766 A ES 537766A ES 8604308 A1 ES8604308 A1 ES 8604308A1
Authority
ES
Spain
Prior art keywords
insect cells
viral
polypeptides
production
eukaryotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES537766A
Other languages
English (en)
Spanish (es)
Other versions
ES537766A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idaho Research Foundation Inc
Original Assignee
Idaho Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24300383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8604308(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idaho Research Foundation Inc filed Critical Idaho Research Foundation Inc
Publication of ES537766A0 publication Critical patent/ES537766A0/es
Publication of ES8604308A1 publication Critical patent/ES8604308A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
ES537766A 1984-01-31 1984-11-19 Un vector para producir un producto genetico por celulas de insectos Expired ES8604308A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57545384A 1984-01-31 1984-01-31

Publications (2)

Publication Number Publication Date
ES537766A0 ES537766A0 (es) 1986-01-16
ES8604308A1 true ES8604308A1 (es) 1986-01-16

Family

ID=24300383

Family Applications (1)

Application Number Title Priority Date Filing Date
ES537766A Expired ES8604308A1 (es) 1984-01-31 1984-11-19 Un vector para producir un producto genetico por celulas de insectos

Country Status (9)

Country Link
EP (1) EP0155476A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS615787A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR850005499A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU3824285A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK518384A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8604308A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR850265B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL73942A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA848495B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879236A (en) * 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
JPS619288A (ja) * 1984-06-21 1986-01-16 Dai Ichi Seiyaku Co Ltd ペプチド類の製法
IL80529A0 (en) * 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
JPS63167797A (ja) * 1985-12-18 1988-07-11 マイクロジエネシス,インコ−ポレイテイド 選択された昆虫宿主細胞中で選択されたポリペプチドを製造する方法
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
EP0260090A3 (en) * 1986-09-08 1988-07-27 David H.L. Bishop Expression of hepatitis b viral antigens from recombinant baculovirus vectors
US5071748A (en) * 1986-09-09 1991-12-10 Genetics Institute, Inc. Mixed baculovirus compositions and uses thereof
ES2008204A6 (es) * 1986-09-09 1989-07-16 Genetics Inst Metodos para producir cuerpos de inclusion polihedrica de composicion mezclada (pib),para coinfectar insectos huespedes y para producir proteinas heterologas en insectos.
US5041379A (en) * 1987-03-16 1991-08-20 American Biogenetic Science, Inc. Heliothis expression systems
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
GB8810808D0 (en) * 1988-05-06 1988-06-08 Wellcome Found Vectors
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
JPH0221955A (ja) * 1988-07-07 1990-01-24 Nippon Steel Corp 流体噴射ノズル
SE8802939D0 (sv) * 1988-08-19 1988-08-19 Kabigen Ab A method for the production and isolation of a fusion protein in eukaryotic cells
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
WO1990005783A1 (en) * 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
DK1378572T3 (da) 1993-05-12 2007-02-05 Genetics Inst Llc BMP-11-sammensætninger
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6027919A (en) 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
WO1995017515A1 (en) * 1993-12-23 1995-06-29 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6165748A (en) 1997-07-11 2000-12-26 Genetics Institute, Inc. Frazzled nucleotide sequences and expression products
US6030619A (en) 1997-08-27 2000-02-29 Chiron Corporation Molecular mimetics of meningococcal B epitopes
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
SG123535A1 (en) 1998-01-14 2006-07-26 Chiron Srl Neisseria meningitidis antigens
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261340B1 (en) 1998-05-01 2017-03-08 GlaxoSmithKline Biologicals SA Neisseria meningitidis antigens and compositions
EP1953229A3 (en) 1998-10-15 2008-12-24 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
JP2003524389A (ja) 1998-12-16 2003-08-19 カイロン コーポレイション ヒトサイクリン依存的キナーゼ(hPNQALRE)
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
ES2522667T3 (es) 1999-04-30 2014-11-17 Novartis Vaccines And Diagnostics S.R.L. Antígenos Neisseriales conservados
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2003527833A (ja) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド 花虫類に由来する発色団/蛍光体、およびそれらの使用法
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
ES2541830T3 (es) 1999-10-29 2015-07-27 Novartis Vaccines And Diagnositics S.R.L. Péptidos antigénicos de Neisseria
US7605246B2 (en) 2000-01-10 2009-10-20 Novartis Vaccines And Diagnostics, Inc. Genes differentially expressed in breast cancer
ES2507100T3 (es) 2000-01-17 2014-10-14 Novartis Vaccines And Diagnostics S.R.L. Vacuna OMV suplementada contra meningococo
US6689599B1 (en) 2000-10-20 2004-02-10 Genetics Institute, Llc Aggrecanase molecules
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US7125701B2 (en) 2001-07-27 2006-10-24 Wyeth Aggrecanase molecules
ATE406912T1 (de) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
ATE439368T1 (de) 2001-12-19 2009-08-15 Univ Chicago Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
EP1476545A4 (en) 2002-01-31 2006-11-29 Wyeth Corp AGGRECANASEMOLEKÜLE
KR20040088059A (ko) 2002-02-05 2004-10-15 와이어쓰 절두된 아그레카나제 분자
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
CA2485703A1 (en) 2002-05-24 2003-12-04 Fred W. Wagner Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
EP1513945A4 (en) 2002-05-24 2008-12-24 Restoragen Inc PROCESS FOR UNIVERSAL ENZYMATIC PRODUCTION OF BIOACTIVE PEPTIDES
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
UA88275C2 (ru) 2003-09-12 2009-10-12 Уайет Композиция, которая включает остеогенный белок и фосфат кальция, которая имеет форму твердого штифта, пригодного для внутрикостной инъекции, способ ее получения и применения
CA2546319A1 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
PT1736541E (pt) 2004-03-29 2013-01-31 Galpharma Co Ltd Nova proteína galectina 9 modificada e sua utilização
EP1732944B1 (en) 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
AU2005265163B2 (en) 2004-06-18 2009-10-01 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
SG158149A1 (en) 2004-12-22 2010-01-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1865940B1 (en) 2005-03-21 2013-02-13 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
PL2054431T3 (pl) 2006-06-09 2012-07-31 Novartis Ag Konformery adhezyn bakteryjnych
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
ES2908934T3 (es) 2007-10-04 2022-05-04 Zymogenetics Inc ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
US8679749B2 (en) 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
EP2247743B1 (en) 2008-02-08 2016-04-06 Ambrx, Inc. Modified leptin polypeptides and their uses
ES2963062T3 (es) 2008-07-23 2024-03-25 Ambrx Inc Polipéptidos G-CSF bovinos modificados y sus usos
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
EA019653B1 (ru) 2008-09-26 2014-05-30 Амбркс Инк. Модифицированные полипептиды эритропоэтина животных и их применение
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US20120283172A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CN103748229A (zh) 2011-07-27 2014-04-23 吉尼松公司 改进的杆状病毒表达系统
RU2710307C2 (ru) 2013-09-12 2019-12-26 Байомарин Фармасьютикал Инк. Векторы экспрессии фактора viii на основе аденоассоциированного вируса
EP3909596A1 (en) 2014-10-24 2021-11-17 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
JP2018535929A (ja) 2015-09-24 2018-12-06 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルス第viii因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤
TN2019000279A1 (en) 2015-11-12 2021-05-07 Res Institute At Nation Wide Childrens Hospital Methods of treating muscular dystrophy
IL259441B2 (en) 2015-11-16 2024-01-01 Res Inst Nationwide Childrens Hospital Materials and methods for the treatment of titin-based myopathies and other titinopathy
AU2017301600B2 (en) 2016-07-26 2022-08-04 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
MY193457A (en) 2017-02-08 2022-10-14 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20200231986A1 (en) 2017-09-29 2020-07-23 Massachusetts Eye And Ear Infirmary Production of adeno-associated viruses in insect cells
MX2020007876A (es) 2018-01-31 2020-12-03 Res Inst Nationwide Childrens Hospital Terapia genica para la distrofia muscular de cinturas tipo 2c.
CA3099704A1 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
MX2020012167A (es) 2018-05-14 2022-07-13 Biomarin Pharm Inc Expresion estable de vectores de aav en sujetos juveniles.
AU2019295779B2 (en) 2018-06-29 2025-04-24 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
KR20210133242A (ko) 2019-02-26 2021-11-05 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 B-사르코글리칸의 아데노 관련 바이러스 벡터 전달 및 근이영양증의 치료
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
MY210230A (en) 2019-08-21 2025-09-04 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
MX2022003681A (es) 2019-09-27 2022-05-10 Biomarin Pharm Inc Caracterizacion de particulas virales de terapia genetica a traves del uso de cromatografia de exclusion de tama?os y las tecnologias de dispersion de la luz en multiples angulos.
JP2023503850A (ja) 2019-11-14 2023-02-01 バイオマリン ファーマシューティカル インコーポレイテッド 肝臓特異的遺伝子療法ベクターによる遺伝性血管浮腫の治療
CN115052974A (zh) 2020-02-10 2022-09-13 生物马林药物股份有限公司 无病毒细胞培养物
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
WO2022094461A1 (en) 2020-11-02 2022-05-05 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
WO2023056436A2 (en) 2021-10-01 2023-04-06 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
JP2023059858A (ja) 2021-10-15 2023-04-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
TW202421788A (zh) 2022-09-22 2024-06-01 美商拜奧馬林製藥公司 用aav基因療法載體治療致心律不整性心肌病
AU2023347220A1 (en) 2022-09-22 2025-05-01 Dinaqor Ag Treatment of cardiomyopathy with aav gene therapy vectors
WO2024151568A1 (en) 2023-01-09 2024-07-18 Biomarin Pharmaceutical Inc. Epigenetic modifiers improve aav gene therapy durability
WO2024238591A2 (en) 2023-05-15 2024-11-21 Biomarin Pharmaceutical Inc. Methods of treating anti-aav seropositive hemophilia patients
WO2025214477A1 (en) 2024-04-12 2025-10-16 Skyline Therapeutics (Shanghai) Co., Ltd. Treatment of genetic cardiomyopathies with aav gene therapy vectors

Also Published As

Publication number Publication date
AU3824285A (en) 1985-08-08
DK518384D0 (da) 1984-10-31
IL73942A0 (en) 1985-03-31
JPS615787A (ja) 1986-01-11
DK518384A (da) 1985-07-01
ZA848495B (en) 1985-09-25
EP0155476A1 (en) 1985-09-25
GR850265B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-05-27
ES537766A0 (es) 1986-01-16
KR850005499A (ko) 1985-08-26

Similar Documents

Publication Publication Date Title
ES8604308A1 (es) Un vector para producir un producto genetico por celulas de insectos
NO303831B1 (no) Isolert DNA-sekvens, vektor, vertscelle, polypeptid og anvendelse in vitro av polypeptidet ved en fremgangsmÕte for transfeksjon av hematopoeseceller med eksogen DNA
KR850003163A (ko) 완전변이 표현 콘트롤 시스템
BG60107B2 (bg) Метод за получаване на еукариотен полипептид
HUT54414A (en) Process for producing systhems expressing amidizing enzymes
AU8065782A (en) Expression of exogenous polypeptides in yeast
NO963358D0 (no) Vertsvektor-system til anvendelse i genterapi
AU586041B2 (en) Expression and secretion of heterologous proteins by yarrowia lipolytica transformants
ES8401134A1 (es) "metodo de producir un cultivo transformante de celulas de vertebrado".
NO175871C (no) Gjærhybridpromotor, gjærhybridvektor, Saccharomyces spec.-vert, samt fremgangsmåte for fremstilling av et polypeptid heterologt med gjær
HUT58798A (en) Process for producing growth factor of parenchimic hepatic celles, the gen for coding this and transformants for producing this factor
KR840005745A (ko) B형 간염비루스 유전자를 삽입한 조환 플라스미드, 이 조환 플라스미드로 전환된 효모 및 b형 간염비루스 표면항원의 제조방법
EP0037723A3 (en) Expression of hormone genomic clones
ATE120486T1 (de) Vektor zur integrationsstellenunabhängigen genexpression in säugetier-wirtszellen.
ATE142264T1 (de) Rekombinante herstellung von a-ketten- polypeptiden von pdgf
HU9202458D0 (en) Expressing systems
KR870005091A (ko) 인체 라이소자임을 제조하는 방법
EP0332416A3 (en) Regulation of expression in mammalian cells
CA1312566C (en) Method for increasing the expression of polypeptides in recombinant cell culture
CA2002862A1 (en) Cloning and expression of a protein which modulates cellular response to type i interferon
GB9003010D0 (en) Gene expression in yeast cells
IE873300L (en) Expression vectors
LV10491A (lv) SAF polipeptids gens promoters un to pielietojums ekspresijai STREPTOMYCES sunas
AU589151B2 (en) New expression control sequence
GR3020035T3 (en) Mammalian cell derived autonomously replicating sequence DNA fragments having affinity to DNA binding proteins